Antibacterial compositions for drug administration
An antibacterial composition having at least one alkyl glycoside, at least one saccharide, and at least one therapeutic agent, wherein the alkyl glycoside has an alkyl chain length from about 12 to about 14 carbon atoms and wherein the saccharide has antibacterial activity, thereby providing for a composition having antibacterial activity.
1 . A method of administering an alkyl saccharide composition comprising, administering a therapeutically effective amount of at least one alkyl saccharide having an alkyl chain length from about 12 to about 14 carbon atoms and at least one saccharide moiety with an antibacterial activity, at least one therapeutic agent, and at least one enhancing agent.
2 . The method as of claim 1 , wherein the alkyl saccharide is a disaccharide.
3 . The method as of claim 1 , wherein the alkyl saccharide further comprises at least one glucose.
4 . The method as of claim 2 , wherein the disaccharide comprises at least one sugar moiety.
5 . The method as of claim 1 , wherein the alkyl saccharide is α-D-glucopyranosyl-β-D-glucopyranoside.
6 . The method as of claim 1 , wherein the composition is administered transmucosally or transdermally.
7 . The method of claim 1 , wherein the therapeutic agent is a drug and the alkyl saccharide is selected from the group consisting of n-Dodecyl-4-O-α-D-glucopyranosyl-β-D-glucopyranoside and n-tetradecyl-4-O-α-D-glucopyranosyl-β-D-glucopyranoside.
8 . The method as of any of the preceding claims, wherein the alkyl saccharide composition is administered topically.
9 . The method of claim 1 , wherein the enhancing agent is EDTA or its salts.
10 . A composition comprising at least one drug selected from the group consisting of insulin, PYY, Exendin-4 or other GLP-1 related peptide, human growth hormone, calcitonin, parathyroid hormone, truncated parathyroid hormone peptides such as PTH 1-34, EPO, interferon alpha, interferon beta, interferon gamma, and GCSF and at least one alkyl saccharide having antibacterial activity.
11 . The composition as of claim 10 , wherein the composition is administered topically.
12 . The composition as of claim 11 , wherein the composition is administered intranasally.
13 . An antibacterial alkyl saccharide composition comprising, a compound selected from the group consisting of n-Dodecyl-4-O-α-D-glucopyranosyl-β-D-glucopyranoside and n-tetradecyl-4-O-α-D-glucopyranosyl-β-D-glucopyranoside.
14 . An aqueous drug composition for transmucocal or transdermal administration comprising, at least one drug and at least one antibacterial agent in a concentration from about 0.05% to about 0.5%.
15 . The composition as of claim 13 , wherein the alkylsaccharide is selected from the group consisting of n-Dodecyl-4-O-α-D-glucopyranosyl-β-D-glucopyranoside and n-tetradecyl-4-O-α-D-glucopyranosyl-β-D-glucopyranoside.
16 . The composition of claim 13 , wherein the alkylsaccharide has an alkyl chain length from 12 to 14 carbon atoms.
17 . The composition as of claims 12 - 16 , wherein the composition is administered topically.
18 . The method of claim 1 , wherein the EDTA or its salts is in a range from about 0.01% to 2% by weight of the composition.